Identify the type of drug-receptor interaction responsible for the effect on platelet aggregation related to AAS. AAS is a drug belonging to the c...
Identify the type of drug-receptor interaction responsible for the effect on platelet aggregation related to AAS.
AAS is a drug belonging to the class of NSAIDs with analgesic, antipyretic, and anti-inflammatory effects in addition to antiplatelet effects.
This drug irreversibly acetylates cyclooxygenase, the enzyme responsible for the production of thromboxane A2 in platelets, which leads to inhibition of platelet aggregation.
The effects of a single dose of AAS persist for 7 to 10 days, although the free drug is cleared much more rapidly from the body.
A) Non-competitive antagonism.
B) Competitive antagonism.
C) Partial agonist.
D) Inverse agonist.
AAS is a drug belonging to the class of NSAIDs with analgesic, antipyretic, and anti-inflammatory effects in addition to antiplatelet effects.
This drug irreversibly acetylates cyclooxygenase, the enzyme responsible for the production of thromboxane A2 in platelets, which leads to inhibition of platelet aggregation.
The effects of a single dose of AAS persist for 7 to 10 days, although the free drug is cleared much more rapidly from the body.
A) Non-competitive antagonism.
B) Competitive antagonism.
C) Partial agonist.
D) Inverse agonist.
Essa pergunta também está no material:
💡 1 Resposta
Ed 
A interação droga-receptor responsável pelo efeito na agregação plaquetária relacionada ao AAS é a irreversível inibição da enzima ciclooxigenase (COX), que é responsável pela produção de tromboxano A2 nas plaquetas. Essa inibição leva à diminuição da agregação plaquetária. Portanto, a alternativa correta é: A) Antagonismo não competitivo.
✏️ Responder
Para escrever sua resposta aqui, entre ou crie uma conta
Outros materiais
Perguntas dessa disciplina
Conteúdos escolhidos para você
17 pág.
96 pág.
1 pág.
6 pág.
Compartilhar